FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-028							

OMB Number:	3235-0							
Estimated average burden								
hours nor resnance.								

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* WITTY ANDREW					2. Issuer Name and Ticker or Trading Symbol G1 Therapeutics, Inc. [GTHX]					(Ch	eck all applic	cable) or	Person(s) to Iss	ner	
(Last) (First) (Middle) C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR.					3. Date of Earliest Transaction (Month/Day/Year) 06/12/2019						Officer below)	(give title	Other (s below)	pecify	
4501 RESEARCH COMMONS, SUITE 100 (Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
RESEAR TRIANG PARK	_	C	27709										led by More t	eporting Person han One Repon	
(City)	(Si	tate)	(Zip)												
		Tab	le I - Non-	Derivat	ve Se	ecurities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned			
Date				2. Transacti Date (Month/Day	Execution Da		Date,	3. Transaction Code (Instr) 8)	on Disposed				es Formally (D) (I) (I	orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		Instr. 4)
		٦	Table II - D (e					uired, Dis , options,				Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date Execution Date	Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$18.47	06/12/2019		A		20,000		(1)	06/12/2029	Common Stock	20,000	\$0.00	20,000	D	

Explanation of Responses:

1. The shares underlying this option will vest in their entirety twelve months after June 12, 2019, subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24.1 - Power of Attorney

<u>James Stillman Hanson,</u> <u>attorney-in-fact</u> <u>06/14/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Anne T. Leland, Brenda L. Meyette, Jacquelyn A. Cannata, Megan N. Gates, Peter N. Cunningham, Verna Krishnamurthy and Hana M. Sahdev of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and Barclay A. Phillips, James Stillman Hanson, Jennifer K. Moses, Becky Daniel and Sandi James of G1 Therapeutics, Inc. signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 13th day of September 2018.

/s/ Andrew P. Witty Andrew P. Witty